文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies.

作者信息

Suryadevara Naveenchandra, Otrelo-Cardoso Ana Rita, Kose Nurgun, Hu Yao-Xiong, Binshtein Elad, Wolters Rachael M, Greninger Alexander L, Handal Laura S, Carnahan Robert H, Moscona Anne, Jardetzky Theodore S, Crowe James E

机构信息

Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.

Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.

出版信息

Nat Microbiol. 2024 Aug;9(8):2128-2143. doi: 10.1038/s41564-024-01722-w. Epub 2024 Jun 10.


DOI:10.1038/s41564-024-01722-w
PMID:38858594
Abstract

Human parainfluenza virus type 3 (hPIV3) is a respiratory pathogen that can cause severe disease in older people and infants. Currently, vaccines against hPIV3 are in clinical trials but none have been approved yet. The haemagglutinin-neuraminidase (HN) and fusion (F) surface glycoproteins of hPIV3 are major antigenic determinants. Here we describe naturally occurring potently neutralizing human antibodies directed against both surface glycoproteins of hPIV3. We isolated seven neutralizing HN-reactive antibodies and a pre-fusion conformation F-reactive antibody from human memory B cells. One HN-binding monoclonal antibody (mAb), designated PIV3-23, exhibited functional attributes including haemagglutination and neuraminidase inhibition. We also delineated the structural basis of neutralization for two HN and one F mAbs. MAbs that neutralized hPIV3 in vitro protected against infection and disease in vivo in a cotton rat model of hPIV3 infection, suggesting correlates of protection for hPIV3 and the potential clinical utility of these mAbs.

摘要

相似文献

[1]
Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies.

Nat Microbiol. 2024-8

[2]
Protective antibodies against human parainfluenza virus type 3 infection.

MAbs. 2021

[3]
Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.

J Virol. 2016-10-14

[4]
Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.

J Virol. 2002-2

[5]
The structural basis of protective and nonprotective human monoclonal antibodies targeting the parainfluenza virus type 3 hemagglutinin-neuraminidase.

Nat Commun. 2024-12-30

[6]
Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.

J Virol. 1990-8

[7]
How a paramyxovirus fusion/entry complex adapts to escape a neutralizing antibody.

Nat Commun. 2024-10-12

[8]
Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo.

mBio. 2013-10-22

[9]
Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity.

Vaccine. 2017-11-16

[10]
Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.

J Virol. 2013-3-20

引用本文的文献

[1]
Molecular Evolution of the () Genes in Human Parainfluenza Virus Type 2.

Microorganisms. 2025-2-12

[2]
Phylogenomic Analyses of the Hemagglutinin-Neuraminidase () Gene in Human Parainfluenza Virus Type 4 Isolates in Japan.

Microorganisms. 2025-2-10

[3]
Molecular Evolutionary Analyses of the Fusion Genes in Human Parainfluenza Virus Type 4.

Microorganisms. 2024-8-9

本文引用的文献

[1]
Cross-protective antibodies against common endemic respiratory viruses.

Nat Commun. 2023-2-13

[2]
Subnanometer structure of an enveloped virus fusion complex on viral surface reveals new entry mechanisms.

Sci Adv. 2023-2-10

[3]
Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape.

STAR Protoc. 2022-6-17

[4]
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.

N Engl J Med. 2022-3-3

[5]
Respiratory syncytial virus: promising progress against a leading cause of pneumonia.

Lancet Glob Health. 2021-12

[6]
Human parainfluenza virus evolution during lung infection of immunocompromised individuals promotes viral persistence.

J Clin Invest. 2021-12-1

[7]
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.

MAbs. 2021

[8]
DeepEMhancer: a deep learning solution for cryo-EM volume post-processing.

Commun Biol. 2021-7-15

[9]
MEGA11: Molecular Evolutionary Genetics Analysis Version 11.

Mol Biol Evol. 2021-6-25

[10]
Protective antibodies against human parainfluenza virus type 3 infection.

MAbs. 2021

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索